摘要
目的探讨癌症患者尿液2,3-吲哚醌含量测定的临床意义。方法采用高效液相色谱法测定健康志愿者及不同系统癌症患者尿液2,3-吲哚醌的含量。结果健康志愿者与胸部、泌尿系统恶性肿瘤患者尿液中2,3-吲哚醌含量有显著性差异(P<0.05);与腹部恶性肿瘤患者之间有极显著性差异(P<0.001);腹部恶性肿瘤患者分别与胸部、泌尿系统恶性肿瘤患者之间有显著性差异(P<0.05);胸部恶性肿瘤患者术前和术后7 d之间,以及不同TNM分期之间无显著性差异(P>0.05)。结论尿液2,3-吲哚醌含量可能为临床诊断癌症的检测指标。
OBJECTIVE To develop a HPLC assay for determination of urinary isatin in cancer patients. METHODS The urinary isatin in 55 malignant tumor patients and 15 healthy volunteers were determined by HPLC. RESULTS The isatin quantification in cancer group, especially the abdominal cancer was significantly higher than that of control group（ P 〈 0. 05 , P 〈 0. 001 ）. The isatin concentration in patients with abdominal cancer group, was significantly higher than that of patients with thoracic or urinary cancer. For thoracic cancer patients, there was no significant difference in isatin concentration in urine between before are after operation, and among different TNM stages. CONCLUSION The isatin concentration of urine might serve as a novel tumor diagnosis marker.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2008年第2期149-151,共3页
Chinese Pharmaceutical Journal
